Trial
NCT01388647
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Vector Oncology
Collaborators
Eisai Inc.
Condition
HER-2 Positive Breast Cancer
Intervention
eribulin
Why stopped
Closed early due to increased hematologic toxicity and possible reduced efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-08-28